CARSON CLOSE: Open Payments
NPI 1073981437 · OGDEN, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$636 in 39 payments from 17 companies in 2025. Trend: 2023 $939 · 2024 $1,094 · 2025 $636
Food & beverage: $636
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $150 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $68 |
| Lilly USA, LLC | 4 | $61 |
| GlaxoSmithKline, LLC. | 3 | $54 |
| AstraZeneca Pharmaceuticals LP | 3 | $52 |
| Amgen Inc. | 2 | $40 |
| SI-BONE, INC. | 1 | $27 |
| Lundbeck LLC | 1 | $24 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
| Janssen Pharmaceuticals, Inc | 1 | $23 |
Products named: VRAYLAR, CAPLYTA, MOUNJARO, QULIPTA, EVENITY, FARXIGA, TRELEGY ELLIPTA, REXULTI.
Industry payments across UT — which companies pay providers there.
